Featured
Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAPORT® (Rizatriptin Oral Film) in the United States
Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in development and commercialization of prescription transdermal products, today announced the execution of a definitive licensing, development and supply...Now Available Through Federal Supply Schedule (FSS)
Contract #V797D-70219 The Only FDA-Approved Prescription Hydrogel and 4% Lidocaine HCl for Pain Associated with Wound Healing and Vasculitis FDA Approved #K092086 Astero®, manufactured by Gensco Pharma, is now available through the Federal Supply Schedule. Astero®...Physician Explores Gout Treatment Options
As seen in Chain Drug Review | May 15, 2017 MIAMI — Gout is an extremely painful form of inflammatory arthritis and the most common form of this type of arthritis in men, according to Dr. Gary Myerson, a founding fellow of the American College of Rheumatology....Advances in Treatment of Painful Wounds
by Marc Alan Brenner, DPM, The Institute for Diabetic Foot Research As seen in Podiatry Management | November 2016 Wound management is one of the most common aspects of podiatric practice. The etiology of the wound may vary from post-surgical, traumatic, or disease...A Review and Case Study of Astero® (Lidocaine HCl 4%), a New Prescription Hydrogel for Painful Wounds
By Marc A. Brenner, DPM | Podiatry Management, Clinical Innovations, The Diabetic Foot.
Wound pain has numerous, often interlinked, causes that may relate to the initial injury, the inflammatory response or infection. Pain may also result from interventions, such as dressing removal, cleansing, debridement, compression therapy, or topical treatments. Pain as a result of trauma, particularly during the dressing change procedure, has been described by patients as the worst part of dealing with a wound.1